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Introduction: Warfarin is a drug used for anticoagulation in diseases, 
especially atrial fibrillation (AF). The effectiveness of warfarin is monitored 
by the International Normalized Ratio (INR) and should be kept between 
2.0 and 3.0 in the AF clinic. This drug the significant variability in dose 
response and the narrow therapeutic index among individuals. However, 
the effective INR level may not be achieved due to some reasons, or the 
time to achieve the effective INR level may lengthen. Our aim in this 
study is to investigate whether there is a difference in terms of dose and 
duration in achieving the effective INR level by the warfarin treatment 
due to the coexistence of AF and stroke between patients with and 
without diabetes mellitus (DM).
Methods: A total of 70 patients whose warfarin treatment was initiated 
due to non-valvular AF and who were diagnosed with acute ischemic 
stroke were included in the study, 30 of these patients were DM patients 
and 40 were non-DM patients. The total dose and time values at 
achieving the effective INR level after the initiation of warfarin treatment 
according to the clinical protocol during follow-ups in hospital were 
statistically compared between the two groups.
Results: In the study, it was found that the total warfarin dose was 
significantly higher in the DM group compared to the non DM group 
(p<0.05). It was detected that the time to achieve the effective INR level 
was also significantly longer in the DM group than in the non-DM group 
(p<0.05).
Conclusion: In the presence of DM diagnosis, the higher dose warfarin 
and longer follow-up are required to achieve effective INR levels in stroke 
patients whose warfarin treatment was initiated due to non-valvular AF.
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Stroke is one of the leading causes of morbidity and mortality and 
is a global health problem (1, 2). Approximately 80% of all strokes are 
ischemic type, and hypertension (HT), DM and AF are the most common 
risk factors. According to the Trial of Org 10172 Acute Stroke Treatment 
(TOAST) classification, cardioembolic stroke accounts for about 30–35% 
of ischemic stroke subtype and the most common etiologic cause is AF 
(3, 4). Due to the increase of the elderly population in communities and 
therefore the increase of AF rate; the cardioembolism continues to be the 
cause of ischemic stroke increasingly compared to the past, and this also 
points to several strategies. Especially in the strokes for which no cause 
can be identified, the idea that the cause is an embolic event is increasing. 
In addition, the presence of paroxysmal AF is more frequently detected 
with long-term monitoring of heart rhythm whose use increasingly 
continues in recent years (5, 6). AF prophylaxis should be done without 
delay in order to prevent the stroke and reduce the recurrence stroke. Oral 
anticoagulant which is vitamin K antagonist (warfarin), is recommended 
for the prophylaxis of thromboembolism caused by AF according to 
current guidelines (Class 1, Level of evidence A). Warfarin is the keystone 
of oral anticoagulant treatment for approximately sixty years and most 
commonly used in AF with a rate of 40–60% (7, 8).
Warfarin has the significant variability in dose response and the narrow 
therapeutic index among individuals. The INR value should be kept 
between 2.0 and 3.0 for most indications. It is targeted that the effective 
INR level for AF should be between 2 and 3 by decreasing or increasing 
the warfarin dose according to the frequent INR measurements (9).
According to our clinical observations; in patients whose warfarin 
treatment was initiated due to ischemic stroke caused by AF, the effective 
INR level can be achieved in longer duration and with higher doses of 
warfarin in the patients with DM compared to the patients without DM. 
The aim of this study is to investigate the effect of DM diagnosis in the 
ischemic stroke patients with non-valvular AF on the dose and duration 
of the warfarin treatment initiated to achieve the effective INR levels.
METHODS
The files of 2337 patients who were followed up for acute ischemic 
stroke by hospitalizing between January 2016 and June 2018in the 
Neurology Clinic of Sakarya University Training and Research Hospital, 
were reviewed retrospectively. Patients whose warfarin treatment was 
initiated according to the clinical protocol due to non-valvular AF at their 
hospitalization, were included in the study (Table 1).
Inclusion criteria: Patients between the ages of 18–95, patients who 
admitted to emergency department due to acute ischemic stroke and were 
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newly diagnosed AF by 12-lead electrocardiography, patients with normal 
INR, patients who did not receive thrombolytic therapy, patients who were 
followed up in inpatient clinic until achieving the effective INR level.
Exclusion criteria: Patients with liver and kidney failure, patients with 
severe heart failure, patients with atrial thrombus or segmental wall 
motion defect detected on echocardiography, patients with antiepileptic-
antibiotic-antifungal-NSAID-statin-amiodarone and antithyroid drug use, 
patients using oral anticoagulant therapy before hospitalization, pregnant 
patients, patients with cachexia or morbid obesity, patients whose warfarin 
treatment was discontinued due to hemorrhagic complications during 
hospitalization, patients using insulin prior to hospitalization, patients 
using oral antidiabetic drugs, patients with high fever.
Ischemic stroke patients whose warfarin treatment was initiated due to 
non-valvular AF were included in the study, 30 of these patients were 
newly diagnosed with DM and 40 were non-DM patients.
The patients were followed up for acute ischemic stroke in clinic, and 
warfarin treatment was initiated due to non-valvular AF was started. All 
of the patients were patients who were follow up in clinic until the level 
of INR becoming to range between 2 and 3.
The clinical protocol of warfarin dose adjustment for effective INR level in 
our clinic is indicated in Table 1.
The time and the total warfarin dose to achieve total effective INR level 
were determined, and these values were statistically compared to detect 
whether there was a significant difference between the groups.
Statistical Analysis
Mean, standard deviation, median lowest, median highest, frequency 
and ratio values were used in the descriptive statistics of the data. The 
distribution of the variables was measured by the Kolmogorov-Smirnov 
test. The Mann-whitney U test was used in the analysis of quantitative 
independent data. The Wilcoxon test was used in the analysis of the 
dependent quantitative data. Chi-square test was used to analyze 
qualitative independent data. SPSS 22.0 program was used in the analyzes.
RESULTS
A total of 30 DM patients (16 males) had a mean age of 72.2±11.9 years. 
A total of 40 patients (14 males) in the non-DM group had a mean age 
of 73.4±12.6 years. When the age and gender distribution of both groups 
were compared, no significant difference was found (p>0.05). In the group 
with and without DM; there was no difference between the two groups 
in terms of hypertension (HT), hyperlipidemia (HL) and coronary artery 
disease (CAD) (p: 0.935, p: 0.583, p: 0.546). Smoking rate was significantly 
higher in patients with DM than in patients without DM (p<0.05). In the 
DM patients group, total warfarin dose to achieve effective range of INR 
was 33.0±13.1 mg, while it was 24.4±7.5 mg in the non-DM patient group 
and statistically higher in the DM group (p<0.05). The time required for 
the INR to achieve the effective range was 4.5±1.5 days in the DM patients 
group, 3.6±0.9 days in the non-DM patients group and significantly 
longer in the DM patients group (p<0.05). The first and last INR values did 
not differ significantly in patients with and without DM (p>0.05) (Table 2).
The warfarin given to the effective range of INR in the HT group and the 
non-HT group did not show any significant difference (p>0.05). In patients 
with and without HL, warfarin dose did not show significant differences 
(p>0.05). In patients with and without CAD, warfarin dose did not show 
significant differences (p>0.05). In the patients between smokers and 
non-smokers warfarin dose did not show significant differences (p>0.05) 
(Table 3).
In both groups, there was a significant increase between the first 
measured INR value and the effective INR values (p<0.05) (Table 4).
DISCUSSION
Warfarin is an anticoagulant agent that acts on vitamin K. Vitamin K 
is required for the function of anticoagulant proteins C and S with 
coagulation factors II, VII, IX and X. Warfarin shows its effect by 
inhibiting the effect of vitamin K on coagulation factors and decreasing 
functional factor concentrations (10). Although warfarin is an important 
anticoagulant agent frequently used in clinical practice, the large 
variability associated with narrow therapeutic index and dose response 
may cause adverse effects such as bleeding. Therefore, in patients who 
have started treatment, the drug doses should be determined according 
to the INR levels to be measured at certain intervals and should be 
continued after achieving the effective INR level. The main goal should 
be to achieve a rapid dose of effective INR, considering that some 
patients may develop high doses of hemorrhage or ineffective INR 
may cause recurrent stroke (11). Dose response relationship change is 
associated with genetic, diet, comorbidities (such as acute disease, liver 
failure, alcohol consumption) and drug-drug interactions (12). Due to the 
complex multistage metabolism of warfarin, the vast majority of their 
interactions are mediated by CYP2C9, 1A2, 2C19 and 3A4 isoenzymes. 
Inhibitors or inducers of these enzymes influence the pharmacological 
activity of warfarin and consequently the INR values. Eventually, adverse 
drug reactions due to these interactions lead to events that can be 
severe, life-threatening, and even fatal. There is no convincing evidence 
that warfarin interferes with any food or food (except vitamin K) through 
the modulation of CYP2C9 activity (13, 14). There are many studies 
examining warfarin metabolism and drug-drug interactions. It is known 
that anti-aging drugs, antibiotic-antifungal drugs, antiepileptic drugs, 
antiarrhythmic drugs, statins, NSAIDs and some central nervous system 
drugs enter drug interaction with warfarin (15–17).
Although its mechanism has not been clearly elucidated in recent years, 
DM is thought to be effective on warfarin dose response. Studies have 
emphasized that increased risk for thromboembolic complications in 
patients with DM may be due to differences in the function of various 
endogenous proteins associated with hemostasis, including protein C and 
tissue factor pathway inhibitors. It is also clear from the available evidence 
that DM patients suffer from various vascular diseases potentially causing 
thromboembolic anxiety (18–23). In a study conducted by Johnson and 
colleagues on 911 patients with DM and warfarin, patients were divided 
into two groups according to HbA1 c (HbA1 c <8 and HbA1 c >8) to 
Table 1. The dose schedule of Warfarin treatment for effective INR 
level
Day of 








Continue with the first dose
3  <1.5
1.5–1.9
Raise the dose to 1.5 times the initial dose




Raise the dose to 1.5–2 times the initial dose




Raise the dose to 2 times the initial dose




Raise the dose to 2 times the initial dose
Raise the dose to 1.5–2 times the initial dose
7  <2 Raise the dose to 2 times the initial dose
Acar et al. Effective INR Level in DM Patients may be DelayedArch Neuropsychiatry 2019;56:273−276
275
 Table 2. Comparison of demographic data, comorbid status, INR dose and duration in DM and non-DM patients
DM (-) DM (+)
p Mean ± s. s. /n-% Median Mean ± s. s. /n-% Median
Age 73.4  ± 12.6 76.5 72.2  ± 11.9 72.5 0.605 m
Gender 
Man 14  35.0%  16  53.3%  
0.125 X²
Woman 26  65.0%  14  46.7%  
HT
 (-) 9  22.5%  7  23.3%  
0.935 X²
 (+) 31 77.5% 23 76.7% 
HL
 (-) 34  85.0%  24  80.0%  
0.583 X²
 (+) 6  15.0%  6  20.0%  
CAD
 (-) 31 77.5% 25 83.3% 
0.546 X²
 (+) 9 22.5% 5 16.7% 
Smoking
 (-) 36  90.0%  21  70.0%  
0.033 X²
 (+) 4  10.0%  9  30.0%  
Warfarin Dose 24.4  ± 7.5 22.5 33.0  ± 13.1 31.3 0.005 m
Effective Dose Duration 3.6  ± 0.9 4.0 4.5  ± 1.5 4.0 0.013 m
HgbA1C 5.8  ± 0.4 5.9 7.2  ± 1.3 6.9 0.000 m
Initial INR 1.1  ± 0.1 1.1 1.0  ± 0.1 1.0 0.069 m
Last INR 2.4  ± 0.3 2.4 2.4  ± 0.3 2.4 0.673 m
 m Mann-Whitney U test/X² Chi-square test
DM, Diabetes mellitus; HT, hypertension; HL, hyperlipidemia; CAD, coronary artery disease; TOAST, Trial of Org 10172 in Acute Stroke Treatment; INR, international normalised 
ratio. 
Table 3. Comparison of warfarin dose in terms of HT, HL, CAD and 
smoking
Warfarin Dose






































m Mann-whitney U test, HT: Hypertension, HL: Hyperlipidemia, CAD: Coronary artery 
disease
Table 4. Comparison of initial and effective INR levels in both groups











investigate whether they affected the mechanism of glycemic control 
anticoagulation and hyperglycaemia did not lead to poor anticoagulation 
(24). Stage and colleagues evaluated the effect of antidiabetic drugs on 
patients receiving warfarin therapy, and emphasized that oral antidiabetic 
and insulin therapy, especially metformin, may reduce the INR level 
during warfarin use (15).
In our study, which was the first study to evaluate the effect of DM on 
achieving effective INR value in patients with acute ischemic stroke who 
had AF-induced ischemic stroke and who started warfarin treatment for 
secondary prophylaxis, patients with DM were found to have a higher 
dose of warfarin and a higher duration to achieve effective INR levels than 
non DM patients. All newly diagnosed DM patients in our study consisted 
of patients who started insulin only during admission for hyperglycemic 
control. Patients with drug use such as antiepileptic, antibiotic, antifungal, 
thyroid hormone, nonsteroidal anti-inflammatory drug, statin and 
amiodarone, which may interact with warfarin, have been excluded. 
According to a study by Minno et al., The exact effect of steady-state 
interactions may not be apparent for 2 to 3 weeks, depending on the 
interacting agent used. Similarly, if the inducer is interrupted, a washout 
period of several weeks may be required before hepatic enzymes 
normalize (16). For this reason, all patients in our study who were trying 
to prevent this effect were advised that both insulin and warfarin therapy 
were started at the same time as hospitalization. It is thought that the 
duration of excess and duration of warfarin dose required to achieve 
effective INR level in DM subjects compared to non DM subjects is due 
to the fact that DM significantly influences anticoagulation but not drug-
drug interactions. For this reason, it can be predicted that patients with 
DM should begin with warfarin at a dose 1.5–2 times higher than the 
routine initial treatment to achieve effective INR levels, thus producing 
faster anticoagulant effects.
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CONCLUSION
In conclusion, it has been found that in patients with DM who started 
treatment with warfarin, DM has achieved higher dose and longer duration 
of effective INR level because it slowed down the anticoagulation process. 
Therefore, if there is no significant haemorrhagic risk in these patients, 
warfarin dosing may be administered at a higher dose than routine 
administration, and the effective dosing of INR may be targeted in a shorter 
time. Future prospective studies should aim to explore this relationship in 
an independent environment and explore possible mechanisms.
Limitations: The most important deficiency in this study is that the study 
protocol is retrospective and the data obtained are examined according to 
the file records. A second shortcoming is that the number of patients is low.
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